 |
0 Diseases |  |
643 Trials |
|
643 Trials |  |
26774 News |  |
| «12...480481482483484485486487488489490...508509» |
- Lartruvo (olaratumab) / Eli Lilly
Enrollment open, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Apr 3, 2015
P1, N=18, Recruiting, Sponsor: Eli Lilly and Company
Not yet recruiting --> Recruiting
- |||||||||| Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
New P3 trial: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A (clinicaltrials.gov) - Apr 2, 2015
P3, N=110, Not yet recruiting, Sponsor: Hoffmann-La Roche
- |||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Trial initiation date, Trial primary completion date: BREACH: Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma. (clinicaltrials.gov) - Apr 1, 2015
P2, N=170, Recruiting, Sponsor: The Lymphoma Academic Research Organisation
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Feb 2016 --> Feb 2017
- triciribine phosphate (PTX-200) / VioQuest, Prescient Therap
Enrollment open, Trial primary completion date, Metastases: PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer (clinicaltrials.gov) - Mar 31, 2015
P1/2, N=56, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
Not yet recruiting --> Recruiting | Initiation date: Dec 2014 --> Mar 2015 | Trial primary completion date: Feb 2016 --> Feb 2017 Suspended --> Recruiting | Trial primary completion date: Jan 2015 --> Jan 2017
- Rituxan (rituximab) / Roche, Epratucyn (epratuzumab) / Gilead
Enrollment change, Metastases: Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - Mar 28, 2015
P2, N=107, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Suspended --> Recruiting | Trial primary completion date: Jan 2015 --> Jan 2017 N=86 --> 107
- thioguanine / Generic mfg.
Trial completion, Minimal residual disease: S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Mar 28, 2015
P2, N=79, Completed, Sponsor: Southwest Oncology Group
N=86 --> 107 Active, not recruiting --> Completed
- | Epratucyn (epratuzumab) / Gilead
Phase classification: Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Mar 26, 2015
P2, N=134, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Phase classification: P1/2 --> P2
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment closed: Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 24, 2015
P3, N=524, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P1/2 --> P2 Recruiting --> Active, not recruiting
- | Adcetris (brentuximab vedotin) / Seagen, Takeda
Enrollment open: AHOD1331: Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (clinicaltrials.gov) - Mar 20, 2015
P3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | doxorubicin hydrochloride / Generic mfg.
Trial completion, Enrollment change: MIRACLE I: Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma (clinicaltrials.gov) - Mar 18, 2015
P=N/A, N=25, Completed, Sponsor: CeloNova BioSciences, Inc.
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=60 --> 25
- |||||| Rituxan (rituximab) / Roche, Rituxan Hycela (rituximab/hyaluronidase) / Biogen, Roche, Halozyme
Enrollment open: A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a (clinicaltrials.gov) - Mar 17, 2015
P3, N=900, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=60 --> 25 Active, not recruiting --> Recruiting
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial primary completion date: ALL Adult Consortium Trial: Adult ALL Trial (clinicaltrials.gov) - Mar 11, 2015
P2, N=112, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- sildenafil / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Trial primary completion date: Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers (clinicaltrials.gov) - Mar 10, 2015
P1, N=50, Active, not recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Jun 2014 --> Jun 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Feb 2015
- | Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Enrollment closed, Trial primary completion date: R-ABVD vs ABVD-RT in Early Stage Hodgkin's Lymphoma (clinicaltrials.gov) - Mar 10, 2015
P3, N=336, Active, not recruiting, Sponsor: Fondazione Michelangelo
Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2016 --> Feb 2015 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2012 --> Feb 2018
- Trial primary completion date: A Phase I/II Trial of VR-CHOP in Lymphoma Patients (clinicaltrials.gov) - Mar 9, 2015
P1/2, N=37, Active, not recruiting, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2012 --> Feb 2018 Trial primary completion date: Mar 2014 --> Dec 2015
- doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Post-Operative Chemoradiation for Extremity & Trunk Soft Tissue Sarcoma (clinicaltrials.gov) - Mar 9, 2015
P1, N=36, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Mar 2014 --> Dec 2015 Trial primary completion date: Jan 2016 --> Jan 2017
- oxaliplatin / Generic mfg., cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment open: Treating Peritoneal Carcinomatosis With PIPAC (clinicaltrials.gov) - Mar 9, 2015
P2, N=10, Enrolling by invitation, Sponsor: Michael Bau Mortensen
Trial primary completion date: Jan 2016 --> Jan 2017 Not yet recruiting --> Enrolling by invitation
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma (clinicaltrials.gov) - Mar 7, 2015
P2, N=65, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center.
Not yet recruiting --> Enrolling by invitation Trial primary completion date: Feb 2015 --> Feb 2016
- | Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap
Trial termination, Metastases: IXAMPLE2: A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer (clinicaltrials.gov) - Mar 7, 2015
P3, N=500, Terminated, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Feb 2015 --> Feb 2016 Completed --> Terminated; Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies.
- Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P1/2 trial: STEFNE: Fasting on Newly Diagnosed Breast Cancer (clinicaltrials.gov) - Mar 7, 2015
P1/2, N=40, Recruiting, Sponsor: Western Regional Medical Center
- | melphalan / Generic mfg., busulfan / Generic mfg.
Trial suspension: Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov) - Mar 5, 2015
P=N/A, N=150, Suspended, Sponsor: Children's Oncology Group
Completed --> Terminated; Interim analysis results showed that ixabepilone did not improve survival compared with control chemotherapies. Active, not recruiting --> Suspended
- | Lartruvo (olaratumab) / Eli Lilly
New P1 trial, Metastases: A Study of Olaratumab in Japanese Participants With Advanced Cancer (clinicaltrials.gov) - Mar 5, 2015
P1, N=18, Not yet recruiting, Sponsor: Eli Lilly and Company
- ||| Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment change, Trial primary completion date, Combination therapy: Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL) (clinicaltrials.gov) - Mar 3, 2015
P2, N=75, Recruiting, Sponsor: Seattle Genetics, Inc.
Active, not recruiting --> Suspended N=50 --> 75 | Trial primary completion date: May 2015 --> Mar 2017
- cisplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Surgery: A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers (clinicaltrials.gov) - Mar 3, 2015
P2, N=4, Terminated, Sponsor: Columbia University
N=50 --> 75 | Trial primary completion date: May 2015 --> Mar 2017 N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Apr 2014; Principal Investigator left institution
- | everolimus / Generic mfg.
Trial completion, Trial primary completion date: RADCHOP: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas (clinicaltrials.gov) - Mar 3, 2015
P1/2, N=46, Completed, Sponsor: Samsung Medical Center
N=20 --> 4 | Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Apr 2014; Principal Investigator left institution Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014
- ||||||| Herceptin (trastuzumab) / Roche
Trial completion: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer (clinicaltrials.gov) - Mar 3, 2015
P3, N=3222, Completed, Sponsor: Sanofi
Recruiting --> Completed | Trial primary completion date: Dec 2013 --> Dec 2014 Active, not recruiting --> Completed
- cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial primary completion date: Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide (clinicaltrials.gov) - Mar 2, 2015
P4, N=18, Recruiting, Sponsor: Texas Tech University Health Sciences Center
Active, not recruiting --> Completed Trial primary completion date: Aug 2015 --> Feb 2016
- Onureg (azacitidine oral) / BMS
Enrollment open: A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma (clinicaltrials.gov) - Mar 2, 2015
P1, N=50, Recruiting, Sponsor: Celgene Corporation
Trial primary completion date: Aug 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- ||||| Enrollment change: Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma (clinicaltrials.gov) - Feb 26, 2015
P3, N=621, Recruiting, Sponsor: Children's Oncology Group
Not yet recruiting --> Recruiting N=803 --> 621
- etoposide IV / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Clinical: Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors (clinicaltrials.gov) - Feb 26, 2015
P0, N=12, Not yet recruiting, Sponsor: Washington University School of Medicine
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Feb 24, 2015
P1, N=248, Recruiting, Sponsor: Hoffmann-La Roche
N=803 --> 621 Initiation date: Sep 2014 --> Jun 2014
- | Enrollment closed, Surgery: Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer (clinicaltrials.gov) - Feb 23, 2015
P3, N=3260, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Sep 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- || Venclexta (venetoclax) / Roche, AbbVie, Walter and Eliza Hall Institute, Gazyva (obinutuzumab) / Roche, Biogen, Nippon Shinyaku, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial initiation date, Combination therapy: CAVALLI: A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (clinicaltrials.gov) - Feb 20, 2015
P1, N=248, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Jun 2014 --> Sep 2014
- Enrollment closed, Trial primary completion date, Metastases: Androgen Deprivation Therapy in Advanced Salivary Gland Cancer (clinicaltrials.gov) - Feb 20, 2015
P2, N=152, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Initiation date: Jun 2014 --> Sep 2014 Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2020
- || dasatinib / Generic mfg.
Trial primary completion date: Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (clinicaltrials.gov) - Feb 19, 2015
P2, N=115, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Dec 2020 Trial primary completion date: Feb 2015 --> Aug 2016
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial primary completion date: Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Feb 19, 2015
P2, N=62, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2015 --> Aug 2016 Trial primary completion date: Mar 2009 --> Mar 2011
- | sorafenib / Generic mfg.
Enrollment change, Metastases: Sorafenib Chemoembolization Evaluation Controlled Trial (clinicaltrials.gov) - Feb 19, 2015
P2/3, N=246, Recruiting, Sponsor: Fourth Military Medical University
Trial primary completion date: Mar 2009 --> Mar 2011 N=398 --> 246
- Neupogen (filgrastim) / Kyowa Kirin, Amgen, Rituxan (rituximab) / Roche
Trial initiation date, Gene therapy: Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov) - Feb 13, 2015
P=N/A, N=5, Not yet recruiting, Sponsor: City of Hope Medical Center
N=398 --> 246 Initiation date: Jan 2015 --> Apr 2015
- bortezomib / Generic mfg., melphalan / Generic mfg., thalidomide / Generic mfg.
Trial primary completion date: UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy (clinicaltrials.gov) - Feb 12, 2015
P3, N=177, Active, not recruiting, Sponsor: University of Arkansas
Initiation date: Jan 2015 --> Apr 2015 Trial primary completion date: Apr 2014 --> Aug 2015
- |||||||||| bortezomib / Generic mfg., cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
New P3 trial: CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Feb 12, 2015
P3, N=236, Not yet recruiting, Sponsor: Sun Yat-sen University
- | doxorubicin hydrochloride / Generic mfg.
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date, Metastases: HD0801: High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients (clinicaltrials.gov) - Feb 12, 2015
P2/3, N=520, Active, not recruiting, Sponsor: Fondazione Italiana Linfomi ONLUS
Trial primary completion date: Apr 2014 --> Aug 2015 Recruiting --> Active, not recruiting | Phase classification: P3 --> P2/3 | N=300 --> 520 | Trial primary completion date: Jun 2014 --> Jan 2015
- Trial completion, Enrollment change: A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide (clinicaltrials.gov) - Feb 12, 2015
P2, N=64, Completed, Sponsor: European Lung Cancer Working Party
Recruiting --> Active, not recruiting | Phase classification: P3 --> P2/3 | N=300 --> 520 | Trial primary completion date: Jun 2014 --> Jan 2015 Recruiting --> Completed | N=43 --> 64
- cixutumumab (IMC A12) / Eli Lilly
Trial completion, Trial primary completion date, Combination therapy, Metastases: Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma (clinicaltrials.gov) - Feb 11, 2015
P2, N=179, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed | N=43 --> 64 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014
- Votrient (pazopanib) / Novartis, BeiGene
Enrollment open, Trial initiation date: Pazopanib Maintenance Phase II (clinicaltrials.gov) - Feb 10, 2015
P2, N=150, Recruiting, Sponsor: Ludwig-Maximilians - University of Munich
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Sep 2014 Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014
- Rituxan (rituximab) / Roche, Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
Trial completion, Enrollment change: Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2015
P2, N=30, Completed, Sponsor: Centre Antoine Lacassagne
Not yet recruiting --> Recruiting | Initiation date: Sep 2014 --> Dec 2014 Recruiting --> Completed | N=63 --> 30
- | Ontak (denileukin diftitox) / Eisai, TSD Japan
Trial completion, Trial primary completion date, Combination therapy: A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma (clinicaltrials.gov) - Feb 10, 2015
P2, N=49, Completed, Sponsor: Yale University
Recruiting --> Completed | N=63 --> 30 Recruiting --> Completed | Trial primary completion date: Nov 2010 --> Dec 2007
- |||||||||| Oncaspar liquid (pegaspargase) / Servier
New P3 trial: Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage (clinicaltrials.gov) - Feb 9, 2015
P3, N=180, Not yet recruiting, Sponsor: Sun Yat-sen University
- | Undisclosed HER2Bi-armed ATC / TransTarget, Barbara Ann Karmanos Cancer Institute
Enrollment change, Surgery: Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery (clinicaltrials.gov) - Feb 6, 2015
P2, N=32, Recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Completed | Trial primary completion date: Nov 2010 --> Dec 2007 N=48 --> 32
- ||||| Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Biomarker, Enrollment closed, Metastases: SCHEARLY: A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer (clinicaltrials.gov) - Feb 6, 2015
P3, N=241, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=48 --> 32 Recruiting --> Active, not recruiting
- Emend intravenous (fosaprepitant) / Merck (MSD), Ono Pharma
Trial primary completion date: Fosaprepitant in Patients Receiving Ifosfamide-based Regimen (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting Trial primary completion date: May 2015 --> May 2016